do not combine dpp-4 inhibitors with glp-1 receptor agonists guidance Frontiers Insight into Structure Activity Relationship
Description
Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management

Figure 3
Increased signaling through exchange proteins directly activated by cAMP (EPACs), specifically EPAC2, and activation of protein kinase A (PKA) follow the rise in cAMP

Nutr Metabol

Clin Endocrinol (Oxf)
obesity vs
